Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

rmulation of CK-1827452 in patients with ischemic cardiomyopathy and angina. Cytokinetics also plans to present data from this trial at the 2009 Heart Failure Congress of the European Society of Cardiology. Top-line data from this trial were included in a Cytokinetics press release in December 2008. The third Phase 2a clinical trial is designed to evaluate an intravenous formulation of CK-1827452 in patients with stable heart failure undergoing clinically indicated coronary angiography in the cardiac catheterization laboratory. Cytokinetics recently initiated its fourth Phase 2a clinical trial of CK-1827452, an open-label, multi-center, multiple-dose trial designed to evaluate and compare the oral pharmacokinetics of both a modified release and an immediate release formulation of CK-1827452 in patients with stable heart failure.

In addition, Cytokinetics has conducted five Phase 1 clinical trials of CK-1827452 in healthy subjects: a first-time-in-humans study evaluating an intravenous formulation, an oral bioavailability study evaluating both intravenous and oral formulations, and three studies of oral formulations: a drug-drug interaction study, a dose proportionality study and a study evaluating modified-release formulations. Data from each of these trials have been reported previously.

Background on Cardiac Myosin Activators and Cardiac Contractility

Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac contractility is driven by the cardiac sarcomere, a highly ordered cytoskeletal structure composed of cardiac myosin, actin and a set of regulatory proteins, and is the fundamental unit of muscle contraction in the heart. The sarcomere represents one of the most thoroughly characterized protein machines in human biology. Current inotropic agents, such as beta-ad
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Sales Horizons, a leader ... blended sales training programs for companies engaged in complex ... used by thousands of salespeople over 25 years in ... program can be customized to address the unique sales ... blended sales training program consists of two parts: ...
(Date:7/30/2014)... July 30, 2014 BCC Research ( ... Markets for Enzymes in Industrial Applications , the global ... nearly $7.1 billion by 2018, registering a five-year compound ... estimated to be recorded in the detergent enzyme segment ... , Enzyme technology has influenced almost every sector of ...
(Date:7/30/2014)... 30, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... and proprietary technologies are used to discover, develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Dubinski as Vice President and Chief Financial Officer. ... and information technology operations for Dyadic and will ...
(Date:7/30/2014)... Mass. , July 30, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, ... unmet medical needs using RNA-targeted technologies, today ... (RXI-109-1402) with RXI-109, for the reduction of ... revision surgery, has been initiated. ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... May 1 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... the,discovery, development and commercialization of novel drugs in ... today,announced that it will host a conference call ... on Wednesday, May 7, 2008 at 10:00,a.m. (EDT). ...
... (NASDAQ: ANPI , TSX: ANP), a global ... it has received 510(k),clearance from the U.S. Food ... and 4-0 of its Quill Self-Retaining System (SRS),Polydioxanone ... a longer-lasting,absorbable suture, which is typically used for ...
... May 1 CryoLife, Inc., (NYSE: CRY ... announced today,that Harvey Morgan has been elected to ... is a Managing Director at Bentley,Associates L.P., an ... than 35 years of investment banking experience with,significant ...
Cached Biology Technology:Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 3Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 2Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 3Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 4Harvey Morgan Joins CryoLife Board of Directors 2
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... cancer treatment has been shown to relieve patients, ... neural transmission between the peripheral and central nervous ... of Radiation Medicine, Chinese Academy of Medical Sciences, ... rat dorsal root ganglia (DRG) to provide relief ... (0, 14.8, 29.6 MBq) were implanted separately into ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... Institute for Aging Research (IFAR) at Hebrew SeniorLife, an affiliate ... specifically milk and yogurt is associated with higher bone mineral ... on the other hand, may be associated with lower BMD ... , these findings suggest that not all dairy products are ...
... reefs are predicted to decline under the pressure of ... survive at seawater temperatures even higher than predicted for ... while most species cannot, is being investigated by researchers ... York University Abu Dhabi (NYUAD). We tend ...
... February, Dennis J. Selkoe and five other "brain teasers" will ... for this honorary doctorate VIB-KU Leuven professors Bart De ... for his scientific insights, but also for his relentless search ... that cause severe damage in the brain. "The ...
Cached Biology News:New study sheds light on link between dairy intake and bone health 2How do corals survive in the hottest reefs on the planet? 2Prevention is better than cure. Also for Alzheimer's disease! 2Prevention is better than cure. Also for Alzheimer's disease! 3Prevention is better than cure. Also for Alzheimer's disease! 4
... AgarACE Enzyme(a) is a unique agarose-digesting ... quantitative recovery of intact DNA or RNA ... thermostable that low melting point (LMP) agarose ... be equilibrated to the reaction temperature before ...
... deoxynucleotidyl transferase (TdT) is an intracellular marker ... thymocytes and minor subpopulation of bone marrow ... increased numbers of TdT cells are found ... and lymphomas. Presence of TdT thus provides ...
Request Info...
... RapidStak is a fast and ... Its high capacity and reliable ... confident walk away time than typical ... of set-up make for a seamless ...
Biology Products: